Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer

12/30/2019 | 04:32am EST
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York, United States

AstraZeneca and Merck's ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer treatments.

The U.S. Food and Drug Administration (FDA) approved the drug's use as a first-line maintenance therapy for patients with BRCA gene mutations whose cancer had spread beyond the pancreas and whose tumours did not worsen after chemotherapy of at least 16 weeks, the British drugmaker said on Monday.

Mutations in BRCA genes impair the ability to repair DNA damage and are typically linked with breast and ovarian cancers, but can occur in other cancers as well.

Lynparza belongs to a class of drugs known as PARP inhibitors, which block what is left of the DNA repair mechanism so cancer cells fail to replicate and a tumour cannot sustain itself.

The drug is now the only approved medicine in biomarker-selected patients with advanced pancreatic cancer.

It is already approved for ovarian and breast cancers, and its latest approval underscores the potential of PARP inhibitors for use in newer indications.

"Metastatic pancreatic cancer patients have been waiting a long time for new therapy options for their devastating disease," said Julie Fleshman, chief executive officer of Pancreatic Cancer Action Network.

Pancreatic cancer is deadly as most patients are diagnosed in advanced stages.

It is expected to claim the lives of nearly 46,000 Americans in 2019, according to the American Cancer Society.

The widely expected approval follows a panel recommendation this month after a study showed Lynparza helped pancreatic cancer patients go nearly twice as long without their disease worsening than those who received a placebo.

Lynparza became the first marketed PARP drug with a U.S. approval for ovarian cancer in 2014 and is key to AstraZeneca's push in oncology and sustaining the company's turnaround.

Other approved PARP inhibitors include GSK's Zejula, Pfizer's Talzenna and Clovis Oncology's Rubraca, but Lynparza sales dwarf their numbers.

AstraZeneca's PARP treatment brought in $847 million (£645.9 million) in sales for the nine months ended Sept. 30. Prior to the latest approval, analysts forecast average sales of $3.1 billion in 2023 for Lynparza.

The London-listed drugmaker has numerous trials lined up for Lynparza and in various combination treatments across different gene pools.

This is also AstraZeneca's second big win this month after the FDA approved its and Daiichi Sankyo's drug to treat an advanced form of breast cancer, four months ahead of schedule.

By Pushkala Aripaka

© Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.44% 7592 Delayed Quote.3.66%
BYD COMPANY LIMITED -1.29% 245.8 End-of-day quote.20.96%
CLOVIS ONCOLOGY, INC. -6.38% 5.58 Delayed Quote.16.35%
DAIICHI SANKYO COMPANY, LIMITED 0.74% 3674 End-of-day quote.3.93%
DNA OYJ 0.00%End-of-day quote.-0.10%
GLAXOSMITHKLINE PLC 1.41% 1413.6 Delayed Quote.5.34%
MERCK & CO., INC. 1.47% 83.38 Delayed Quote.1.93%
TELENOR ASA -0.03% 146.15 Real-time Quote.0.17%
THE LEAD CO., INC. 1.69% 842 End-of-day quote.0.24%
THE PROCTER & GAMBLE COMPANY -0.75% 134.78 Delayed Quote.-3.13%
All news about ASTRAZENECA PLC
02:23pASTRAZENECA : Brazil's health agency approves the use of two vaccines
02:10pASTRAZENECA : Brazil Starts Its Covid-19 Vaccine Rollout -- 3rd Update
01:52pASTRAZENECA : Brazil Authorizes Use of Two Covid-19 Vaccines -- Update
01:39pBrazil Authorizes Use of Two Covid-19 Vaccines
01:28pASTRAZENECA : Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shot..
10:07aASTRAZENECA : Brazil regulator to decide on emergency use of Sinovac, AstraZenec..
03:55aSwiss to get Moderna vaccine in tranches until mid-year - Blick
01:32aTHE LATEST : Pakistan approves Oxford-AstraZeneca vaccine
01/16THE LATEST : Biden elevates science adviser to Cabinet level
01/16ASTRAZENECA : India starts world's largest COVID-19 vaccination drive
More news
Financials (USD)
Sales 2020 26 400 M - -
Net income 2020 2 992 M - -
Net Debt 2020 13 217 M - -
P/E ratio 2020 43,0x
Yield 2020 2,73%
Capitalization 135 B 135 B -
EV / Sales 2020 5,63x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,21 $
Last Close Price 103,14 $
Spread / Highest target 51,3%
Spread / Average Target 22,4%
Spread / Lowest Target -18,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993